Monitoring of Donor‐Derived Cell‐Free DNA by Short Tandem Repeats: Concentration of Total Cell‐Free DNA and Fragment Size for Acute Rejection Risk Assessment in Liver Transplantation

• Published in: Liver transplantation Vol. 28; no. 2; pp. 257 - 268
• Main Authors: Fernández‐Galán, Esther, Badenas, Celia, Fondevila, Constantino, Jiménez, Wladimiro, Navasa, Miquel, Puig‐Butillé, Joan Anton, Brunet, Mercè
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2022
• Subjects: Biomarkers; Cell-Free Nucleic Acids; Deoxyribonucleic acid; Diagnosis; DNA; Feasibility studies; Graft rejection; Graft Rejection - diagnosis; Humans; Liver transplantation; Liver Transplantation - adverse effects; Liver transplants; Microsatellite Repeats; Patients; Pilot Projects; Polymerase chain reaction; Risk Assessment; Short tandem repeats
• ISSN: 1527-6465; 1527-6473
• DOI: 10.1002/lt.26272

Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis of acute rejection (AR). Recently, donor‐derived cell‐free DNA (ddcfDNA) has emerged as a noninvasive biomarker to assess graft integrity. This study evaluated the feasibility of measuring the ddcfDNA through short tandem repeat (STR) analysis by quantitative fluorescent‐polymerase chain reaction (QF‐PCR) and to assess the role of the concentration and fragment size of total cfDNA as AR biomarkers. The total concentration and fragment size of cfDNA and the ddcfDNA percentage were monitored in plasma of 20 patients without rejection and 7 patients with T‐cell–mediated AR during the first 3 months after LT. The median ddcfDNA percentage was 3‐fold higher before AR diagnosis (34.8%; P < 0.001) and moderately higher at AR confirmatory diagnosis (23.8%; P = 0.049) compared with that of nonrejector patients (10.6%), showing a better performance (area under the curve = 84.6%) than conventional LFTs to predict the risk of rejection within the first 2 weeks following LT. The fraction of 100‐250‐bp cfDNA fragments was higher at AR diagnosis compared with that of nonrejector patients (68.0% versus 57.9%, P = 0.02). STR amplification by QF‐PCR may be an alternative strategy for rapid ddcfDNA quantification, which is easily implementable in clinical laboratories. The results of this pilot study indicate that ddcfDNA increases very early, even 1‐2 weeks before the diagnosis of AR, and so it could be useful as a prognostic biomarker in improving patient risk stratification. https://www.wileyhealthlearning.com/#/online-courses/d1f49d22-fe8c-44ee-b5c9-5a26cd1abeda